- Home
- NXDT vs CRDF Comparison
NXDT vs CRDF Comparison
Compare NXDT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXDT
- CRDF
- Stock Information
- Founded
- NXDT 2012
- CRDF 1999
- Country
- NXDT United States
- CRDF United States
- Employees
- NXDT N/A
- CRDF N/A
- Industry
- NXDT Investment Managers
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NXDT Finance
- CRDF Health Care
- Exchange
- NXDT Nasdaq
- CRDF Nasdaq
- Market Cap
- NXDT 170.0M
- CRDF 152.3M
- IPO Year
- NXDT N/A
- CRDF N/A
- Fundamental
- Price
- NXDT $3.11
- CRDF $2.24
- Analyst Decision
- NXDT
- CRDF Strong Buy
- Analyst Count
- NXDT 0
- CRDF 5
- Target Price
- NXDT N/A
- CRDF $11.10
- AVG Volume (30 Days)
- NXDT 133.6K
- CRDF 788.8K
- Earning Date
- NXDT 01-01-0001
- CRDF 10-29-2025
- Dividend Yield
- NXDT 9.66%
- CRDF N/A
- EPS Growth
- NXDT N/A
- CRDF N/A
- EPS
- NXDT 0.99
- CRDF N/A
- Revenue
- NXDT N/A
- CRDF $545,000.00
- Revenue This Year
- NXDT N/A
- CRDF N/A
- Revenue Next Year
- NXDT N/A
- CRDF N/A
- P/E Ratio
- NXDT $6.41
- CRDF N/A
- Revenue Growth
- NXDT N/A
- CRDF N/A
- 52 Week Low
- NXDT $5.89
- CRDF $1.90
- 52 Week High
- NXDT $13.07
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- NXDT 33.04
- CRDF 48.03
- Support Level
- NXDT $3.06
- CRDF $2.20
- Resistance Level
- NXDT $3.66
- CRDF $2.36
- Average True Range (ATR)
- NXDT 0.13
- CRDF 0.10
- MACD
- NXDT -0.02
- CRDF -0.00
- Stochastic Oscillator
- NXDT 10.00
- CRDF 42.84
About NXDT NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust is a publicly traded REIT focused on opportunistic real estate investments in the United States. Their portfolio includes diverse commercial properties and investments across various real estate sectors and capital structures. The revenue sources of the company include rental income from office and retail properties, interest income from debt investments, dividend income from equity investments, and other ancillary income from tenants. The company operates through its operating partnership and wholly owned subsidiaries.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.